Trials / Completed
CompletedNCT05769478
Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA
A Proof of Concept Study of the Effect of Amifampridine (Firdapse®) on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA (Botox®, BTX-A)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Wake Forest University Health Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
if amifampridine can improve neuromuscular transmission in muscles previously injected with OnabotulinumtoxinA (BTX-A)
Detailed description
Amifampridine may also be effective in treating the sequelae of botulinum toxin injections and this study will determine if neuromuscular transmission as measured by single fiber electromyography is improved in patients treated with BTX-A following administration of amifampridine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amifampridine | a single dose of amifampridine (20mg) will be orally administered |
Timeline
- Start date
- 2023-09-15
- Primary completion
- 2024-10-29
- Completion
- 2024-10-29
- First posted
- 2023-03-15
- Last updated
- 2025-02-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05769478. Inclusion in this directory is not an endorsement.